LINC00963 and ovarian cancer: Mechanistically, most studies by far have suggested LINC00963 acts through the lncRNA/miRNA/mRNA axis, such as miR-608/NACC1 in melanoma (Jiao et al. 2018), miR-214-5p/RAB14 in esophageal cancer (Liu et al. 2020a, b), miR-378 g/CHI3L1 in ovarian cancer (Liu et al. 2020a, b), miR-542-3p/NOP2 in prostate cancer (Sun et al. 2020), and miR-625/HMGA1 and miR-324-3p/ACK1 in breast cancer (Zhang et al. 2019; Wu et al. 2020).